Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Average Rating of “Buy” by Brokerages

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have received an average rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $42.75.

Several research analysts recently weighed in on the company. Zacks Research raised Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Leerink Partners began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating and a $36.00 target price on the stock. Evercore started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating on the stock. Wall Street Zen lowered shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, William Blair started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating for the company.

Kailera Therapeutics Stock Performance

NASDAQ KLRA opened at $17.69 on Friday. The business’s 50 day moving average price is $20.47. Kailera Therapeutics has a twelve month low of $16.76 and a twelve month high of $28.23. The stock has a market cap of $2.29 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its earnings results on Tuesday, May 26th. The company reported ($3,650.00) earnings per share (EPS) for the quarter.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.